PET/CT for Therapy Response Assessment in Lymphoma

被引：160

作者：

Hutchings, Martin ^{[1
,2
]}

Barrington, Sally F. ^{[3
,4
]}

机构：

[1] Copenhagen Univ Hosp, Dept Oncol, Finsen Ctr, Rikshosp, DK-2100 Copenhagen O, Denmark

[2] Copenhagen Univ Hosp, Dept Haematol, Rikshosp, DK-2100 Copenhagen O, Denmark

[3] Kings Coll London, PET Imaging Ctr, London WC2R 2LS, England

[4] Guys & St Thomas Fdn NHS Trust, Div Imaging, London, England

来源：

JOURNAL OF NUCLEAR MEDICINE | 2009年 / 50卷

关键词：

F-18-FDG; PET; PET/CT; lymphoma; response monitoring; response-adapted therapy; POSITRON-EMISSION-TOMOGRAPHY; NON-HODGKINS-LYMPHOMA; HIGH-DOSE CHEMOTHERAPY; LARGE-CELL LYMPHOMA; INTERIM FDG-PET; PROGNOSTIC VALUE; FOLLOW-UP; INTERNATIONAL WORKSHOP; AGGRESSIVE LYMPHOMA; MALIGNANT-LYMPHOMA;

D O I：

10.2967/jnumed.108.057190

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

PET with F-18-FDG is a standard staging procedure for most lymphoma subtypes. Performed during and after therapy for Hodgkin lymphoma (HL) and aggressive non-Hodgkin lymphoma (NHL), F-18-FDG PET results have a high prognostic value and correlate with survival. F-18-FDG PET has been incorporated into revised response criteria for aggressive lymphomas, and several ongoing trials are under way to investigate the value of treatment adaptation based on early F-18-FDG PET results for HL and aggressive NHL. There is little evidence to support the use of F-18-FDG PET for monitoring of the treatment of indolent lymphomas and for routine use in the surveillance setting. So that trial results can be compared and translated easily into clinical practice, uniform and evidence-based guidelines for the interpretation and reporting of response monitoring scans are warranted. Because it is still not proven that the use of interim F-18-FDG PET can improve patient outcomes, we recommend examination of the use of F-18-FDG PET for response monitoring in appropriately designed clinical trials.

引用

页码：21S / 30S

页数：10

共 92 条

[11] RESIDUAL MASS IN LYMPHOMA MAY NOT BE RESIDUAL DISEASE [J].

CANELLOS, GP .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (06) :931-933

[12] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].

Cheson, BD ;

Horning, SJ ;

Coiffier, B ;

Shipp, MA ;

Fisher, RI ;

Connors, JM ;

Lister, TA ;

Vose, J ;

Grillo-López, A ;

Hagenbeek, A ;

Cabanillas, F ;

Klippensten, D ;

Hiddemann, W ;

Castellino, R ;

Harris, NL ;

Armitage, JO ;

Carter, W ;

Hoppe, R ;

Canellos, GP .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253

[13] Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[14]

*CLINICALTRIALS, FDG PET STRAT R DICE

[15]

*CLINICALTRIALS, FLUD F 18 POS EM TOM

[16]

*CLINICALTRIALS, TAIL TRATM B CELL NO

[17]

ClinicalTrials.gov, HD16 EARL STAG HODGK

[18]

ClinicalTrials.gov, HIGH DOS CHEM STEM C

[19]

ClinicalTrials. gov, HD18 ADV STAG HODGK

[20]

ClinicalTrials.gov, POS EM TOM PET AD CH

← 1 2 3 4 5 6 7 8 9 10 →